SCHEDULE: TCG Crossover Boosts Tango Therapeutics Stake to 7%

TCG Crossover Fund II, L.P., along with affiliated entities and individual Chen Yu, has increased its beneficial ownership in Tango Therapeutics, Inc. to 7.0%, acquiring 10,147,867 shares.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu (collectively, the Reporting Persons) have filed an amendment to their Schedule 13G, increasing their beneficial ownership of Tango Therapeutics, Inc. common stock.
• The Reporting Persons now beneficially own 10,147,867 shares, representing 7.0% of the class of securities.
• This holding includes 9,081,201 shares of common stock and 1,066,666 shares underlying Pre-Funded Warrants exercisable within 60 days.
• The filing is an amendment to a previous Schedule 13G, with prior amendments filed on November 20, 2024, November 14, 2025, February 17, 2026, and May 15, 2026.
• The total number of outstanding shares used for percentage calculation is 145,714,648, based on the issuer's Form 10-Q filed on May 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not dominant ownership stake. The disclosure indicates continued investment interest without immediate signs of a control-seeking motive.

Positives

• Increased investment from TCG Crossover, indicating confidence in Tango Therapeutics' potential.
• The stake of 7.0% represents a significant holding, suggesting a substantial commitment.
• The inclusion of exercisable warrants indicates a forward-looking investment strategy.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• The beneficial ownership is capped by a 'Beneficial Ownership Limitation' of 9.99%, preventing a controlling stake through warrant exercise.

Risks

• The Pre-Funded Warrants contain a Beneficial Ownership Limitation (9.99%) which restricts further exercise if it would exceed this threshold, potentially limiting future increases in ownership.
• The filing does not detail specific risks related to Tango Therapeutics' operations or market position, as it is primarily a disclosure of beneficial ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company itself. The inclusion of exercisable warrants suggests a continued interest in the company's future performance by the reporting persons.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
• The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.
• Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

Industry Context

StockSavvy.ai notes that significant stake increases by investment funds like TCG Crossover often signal a belief in the target company's growth prospects, particularly in the biotechnology sector where Tango Therapeutics operates. This filing indicates sustained investor interest in the company's pipeline and development progress.

Stakeholder Impact

• Shareholders: The increased stake by TCG Crossover may be viewed positively, suggesting continued investor confidence, but the 7.0% holding does not imply control.
• Management: The filing is a routine disclosure and does not directly indicate changes in management's strategic direction.
• Creditors/Suppliers: No direct impact is indicated by this ownership filing.

Next Steps

• The Reporting Persons will continue to monitor their beneficial ownership levels in Tango Therapeutics, Inc.
• The Pre-Funded Warrants are exercisable within 60 days, subject to the Beneficial Ownership Limitation.

Key Dates

Keywords

Tango Therapeutics, TCG Crossover, Schedule 13G, Beneficial Ownership, Pre-Funded Warrants, Investment, Securities